[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depressive-episode-mde\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depressive-episode-mde":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,74,124,150],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645267",false,"NCT07681492","Belief Update: The Effects of Depression and Antidepressants in Older People","OLDBELIEFS","Inclusion Criteria for patients with major depressive disorder :\n\n* Patient over 65 years old in outpatient care\n* Patients with major depressive disorder or patients with bipolar major depressive disorder as evaluated by the Mini International Neuropsychiatric Interview (MINI) semi-structured interview for the group suffering from depression\n* Absence of cognitive impairment as evidenced by an MMSE (Mini Mental State Examination) ≥ 24\n* MADRS ≥ 20\n* MMSE ≥ 24\n* Change of antidepressants\n* Person affiliated with a social security scheme\n* Patients who have received informed information about the study and have signed a consent form to participate in the study\n\nExclusion Criteria with major depressive disorder :\n\n* mental disorders other than mood disorders : attention deficit dissorder, borderline personality disorder, schizophrenia, autism spectrum disorder, anorexia-bulimia disorder, obsessive-compulsive disorder, anxiety disorders and substance use disorder (except tobacco).\n* Inability to understand task instructions and perform the behavioral task\n* Neurological or neurosurgical comorbidities\n* Major visual impairment\n* Adults under state medical aid\n* Adults under legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty\n\nInclusion Criteria for patients with major depressive disorder :\n\n* Absence of psychiatric disorders attested by administration of the MINI\n* Absence of cognitive impairment as evidenced by an MMSE ≥ 24",true,"ALL","65 Years",{"count":19,"type":20},62,"ESTIMATED","INTERVENTIONAL",[23],"NA","People in good health do not perceive the future in the same way as those suffering from depression. This difference in perception affects behaviour and emotions and warrants further investigation, both before and after treatment with antidepressants. Research shows that past negative experiences with medication can reduce the effectiveness of treatment, whilst positive expectations can increase it. It is important to gain a better understanding of how antidepressants influence the way in which elderly people with major depressive disorder (MDD) change their beliefs, and to determine whether an improvement in their depressive symptoms is linked to these changes in their beliefs. This study aims to understand whether antidepressants can alter the way people view the future and whether this contributes to their effectiveness. It also seeks to determine whether patients' expectations regarding treatment influence clinical outcomes, and whether changes in their mood may in turn affect these expectations. The study will involve 31 patients aged 65 and over who are suffering from a depressive disorder and require a change of antidepressant, and 31 healthy subjects, also aged 65 and over. The participants' involvement will last for 12 weeks.\n\nDuring a medical consultation, once the doctor has checked that the participant meet all the study's eligibility criteria, they will ask for the participant consent to take part in the study. The participant will then be asked to answer one question about what you hope to gain from the new antidepressant treatment that the doctor will prescribe for the participant. Finally, the participant will carry out a belief-updating exercise, which involves : presenting the participant with a series of events and ask them to indicate how likely they think each of them is to occur, and then. Once they have received further information about these events, ask them to reassess the likelihood of them occurring. This task will be carried out again 12 weeks after the participant start taking their antidepressant, during a consultation required as part of their individual care plan. From the first week of antidepressant treatment until week 12, the participant will be contacted by telephone once a week to answer two short questions about their expectations regarding the treatment and any changes in your mood.",[26,27,28,29],"Major Depressive Episode (MDE)","Beliefs","Beliefs About Future","Depression",[26,27,31,29],"Beliefs about future","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-01-14",{"date":40,"type":20},"2027-10",{"name":42,"class":43},"Hospital Center Guillaume Régnier","OTHER",2,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100638488","NCT07621237","A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)","HORIZON","Inclusion Criteria:\n\n* Primary DSM-5 diagnosis of current MDD.\n* The duration of the current MDE must be between 6 weeks and 18 months.\n* Without psychotic or catatonic features.\n* Capable of reading and understanding English and able to provide written informed consent to participate.\n\nExclusion Criteria:\n\n* Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa,\n* Diagnosis of borderline personality disorder that is known, suspected\n* Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD.\n* Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence.\n* History of substance use disorder and\u002For alcohol use disorder during the preceding 12 months\n* Use of antidepressants (including ketamine\u002Fesketamine, St. John's Wort, S-adenosyl methionine, and\u002For trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)","18 Years",{"count":54,"type":20},360,[56],"PHASE2","The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are:\n\nDoes TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL?\n\nResearchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder.\n\nParticipants will:\n\nTake TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests",[26,59,29],"Major Depressive Disorder (MDD)",[29,61,62],"TNX-102 SL","Cyclobenzaprine","2026-06-01",{"date":65,"type":36},"2026-06-02",{"date":67,"type":20},"2026-06",{"date":69,"type":20},"2028-02",{"name":71,"class":72},"Tonix Pharmaceuticals, Inc.","INDUSTRY",25,{"id":75,"slug":4,"hasResults":10,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":10,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100577917","NCT06804525","LHC-CIDI-5 in Hong Kong","Use of Life History Calendars to Enhance Measurement of Lifetime Experience With Mental Disorders in Hong Kong.","Inclusion Criteria:\n\n* All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters\n* Live in the address sampled from the Census and Statistics Department List of Quarters\n* Reside in Hong Kong for at least six months in the past year\n* Able to read and communicate in Chinese or English\n* Without linguistic or cognitive difficulties\n\nExclusion Criteria:\n\n* Domestic workers","25 Years",{"count":82,"type":20},2500,"OBSERVATIONAL","The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders.\n\nTo mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study.\n\nIn a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation.\n\nThis experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.",[26,59,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Persistent Depressive Disorder (PDD)","Suicidal Ideation","Suicidal Plan","Suicidal Attempt","Suicidal Gesture","Nonsuicidal Self-Injury","Manic Episode","Hypomanic","Bipolar I Disorder","Bipolar Sub Disorder","Bipolar II Disorder","Generalized Anxiety Disorder (GAD)","Intermittent Explosive Disorder (IED)","Panic Attack","Panic Disorder","Obsessive-Compulsive Disorder (OCD)","Posttraumatic Stress Disorder (PTSD)","PCL-SC PTSD","PCL-5 PTSD","Alcohol Use Disorder (AUD)","Substance Use Disorder (SUD)",[108,109,110,111,112,113],"Life History Calendar","CIDI","Recall bias","Retrospective reporting","Lifetime prevalence","Mental disorders","2026-03-09",{"date":116,"type":36},"2026-03-10",{"date":118,"type":36},"2025-01-18",{"date":120,"type":20},"2027-04",{"name":122,"class":43},"The University of Hong Kong",1,{"id":125,"slug":4,"hasResults":10,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":10,"sex":16,"minAge":52,"maxAge":17,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":123},"100612848","NCT07258914","Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)","Feasibility and Efficacy of rTMS in Depression in Individuals With Autism Spectrum Disorder (ASD)","DEPASS'R","Inclusion Criteria:\n\n* Patient with a diagnosis of ASD validated by a psychiatrist or line 2\n* Patient aged 18 to 65...\n* Patients suffering from EDM (MADRS greater than 20)\n* No change in treatment in the month prior to inclusion\n* Patients affiliated with or entitled to social security\n* Patients who have received informed information about the study and have signed a consent form to participate in the study\n\nExclusion Criteria:\n\n* Patients with psychiatric comorbidity (decompensated manic state, schizophrenic disorder)\n* Pregnancy at the time of inclusion\n* Patients with contraindications to rTMS and MRI (history of epilepsy, neurological stimulator, pacemaker, cardiac defibrillator, cardiac prosthesis, vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metal fragments in the eyes, claustrophobia)\n* Adults under legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty, persons hospitalised under compulsion (SDT, SDRE).",{"count":73,"type":20},[23],"Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population.\n\nHowever, treating depression in people with ASD is complicated by the lack of guidelines. Antidepressants appear to be less effective and less well tolerated than in the general population.\n\nrTMS (repetitive transcranial magnetic stimulation) is a technique that stimulates the brain in a painless and non-invasive way. This technique is well tolerated and has very few side effects (headaches, fatigue). It is now used routinely in clinical practice to treat resistant depression, with satisfactory results.\n\nA few studies using rTMS in depression in people with ASD have shown encouraging results and avenues for improvement.\n\nIt could therefore be interesting to conduct a therapeutic study with rTMS on depression in people with ASD, following the avenues for improvement proposed by previous studies.\n\nThe main objective is to evaluate the effectiveness of rTMS in depressed patients with ASD by looking at changes in mood before and after treatment. The investigator will also look at the effects on executive and attentional functions and repetitive behaviors, as well as treatment tolerance.",[135,29,26],"Autism Spectrum Disorder",[135,29,26,137,138,139,140,141],"Transcranial Magnetic Stimulation","Repetitive Transcranial Magnectic Stimulation (rTMS)","rTMS","Neurodivergent","executive and attentional function","2025-11-21",{"date":144,"type":36},"2025-12-02",{"date":146,"type":36},"2024-12-19",{"date":148,"type":20},"2026-02-19",{"name":42,"class":43},{"id":151,"slug":4,"hasResults":10,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":10,"sex":16,"minAge":52,"maxAge":17,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":123},"100595389","NCT07031817","Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder","Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder in Patients With a Characterized Depressive Episode in Primary Care","BIPOVITE","Inclusion Criteria :\n\n* Cis man, cis woman, trans man, trans woman or non-binary,\n* Aged 18 to 65 years old,\n* Meets the DSM-5 criteria for the diagnosis of moderate to severe EDC and is eligible for antidepressant treatment.\n\nNon-Inclusion Criteria :\n\n* Patients under guardianship or trusteeship,\n* Patients with schizophrenia according to DSM-5 criteria,\n* Patients who have received psychotropic treatment in the 5 days prior to inclusion (or 21 days for fluoxetine or aripiprazole), with the exception of benzodiazepines and hydroxyzine at the doses and in compliance with the indications of the Marketing Authorisations,\n* Patients with an unstable physiological state or a serious and symptomatic medical condition in the opinion of the investigator,\n* Pregnant or breast-feeding patients,\n* Patients with a known autoimmune disease, in particular Crohn's disease or thyroiditis, or any other pathology which could, in the opinion of the investigator, modify the blood concentration of immune biomarkers,\n* Patients unable to give informed consent to participate in the study or who cannot be given informed information,\n* Patients not covered by a social security scheme,\n* Patients participating in another interventional study on the day of inclusion,\n* Patients under court protection,\n* Patients vaccinated less than 30 days ago,\n* Patients with difficulties reading, understanding or speaking French.\n\nExclusion Criteria :\n\n* Participants will have the right to withdraw their consent at any time for any reason whatsoever without any prejudice to them,\n* The investigator may prematurely exclude a subject from the study, in agreement with the sponsor, if the subject presents one or more exclusion criteria,\n* Diagnosis of schizophrenia during follow-up or any other diagnosis that would lead to a change in the initial EDC diagnosis,\n* Any condition or situation which, in the opinion of the investigator, would be incompatible with the continuation of the study or which would lead to a bias in the management of the data.",{"count":158,"type":20},623,[23],"The goal of this interventional clinical trial is to assess the diagnostic performance of a composite diagnostic medical devise based on blood-based in vitro diagnostic device and Mood Disorder Questionnaire (MDQ) in identifying bipolar disorder among adult patients presenting with a current major depressive episode in primary care. The study will compare the results of the medical device diagnostic test to those of standardized psychiatric clinical evaluation, to evaluate its sensitivity, specificity, and overall clinical utility.\n\nThe main research questions are :\n\n* Can the investigational medical device accurately distinguish bipolar disorder from unipolar depression ?\n* How does its diagnostic accuracy compare with validated psychiatric questionnaires commonly used in clinical practice ?\n\nParticipants will :\n\n* Provide a blood sample for biomarker analysis using the investigational diagnostic device.\n* Complete a few validated psychiatric assessment tools (e.g., MDQ, MINI).\n* Share sociodemographic and clinical data relevant to psychiatric evaluation.",[162,26,163,164],"Bipolar Disorder (BD)","Primary Care","Major Depression",[166,167,168,169,170,171,172,173,174,175],"bipolar disorder","major depressive episode","primary care","composite medical device","blood biomarkers","mood depression questionnaire","diagnosis","composite diagnostic tool","in vitro diagnostic test","blood biomarker-based algorithm","2025-10-02",{"date":178,"type":36},"2025-10-07",{"date":180,"type":36},"2025-09-30",{"date":182,"type":20},"2028-07-01",{"name":184,"class":43},"University Hospital, Montpellier",""]